Quarterly Report (10-q)

0001413119 false --12-31 Q3 Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited P2Y Unlimited Unlimited Unlimited P3Y P3Y P3Y 0001413119 2022-01-01 2022-09-30 0001413119 2022-11-14 0001413119 2022-09-30 0001413119 2021-12-31 0001413119 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001413119 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001413119 us-gaap:CommonClassAMember 2022-09-30 0001413119 us-gaap:CommonClassAMember 2021-12-31 0001413119 us-gaap:CommonClassBMember 2022-09-30 0001413119 us-gaap:CommonClassBMember 2021-12-31 0001413119 2021-01-01 2021-12-31 0001413119 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001413119 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 0001413119 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001413119 us-gaap:CommonClassBMember 2021-01-01 2021-12-31 0001413119 2022-07-01 2022-09-30 0001413119 2021-07-01 2021-09-30 0001413119 2021-01-01 2021-09-30 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2022-06-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2022-06-30 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2022-06-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001413119 us-gaap:RetainedEarningsMember 2022-06-30 0001413119 2022-06-30 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2021-12-31 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2021-12-31 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2021-12-31 0001413119 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001413119 us-gaap:RetainedEarningsMember 2021-12-31 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2020-12-31 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2020-12-31 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2020-12-31 0001413119 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001413119 us-gaap:RetainedEarningsMember 2020-12-31 0001413119 2020-12-31 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2021-06-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2021-06-30 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2021-06-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001413119 us-gaap:RetainedEarningsMember 2021-06-30 0001413119 2021-06-30 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2022-07-01 2022-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2022-07-01 2022-09-30 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2022-07-01 2022-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001413119 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2022-01-01 2022-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2022-01-01 2022-09-30 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2022-01-01 2022-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001413119 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2021-01-01 2021-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2021-01-01 2021-09-30 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2021-01-01 2021-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001413119 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2021-07-01 2021-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2021-07-01 2021-09-30 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2021-07-01 2021-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001413119 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2022-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2022-09-30 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2022-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001413119 us-gaap:RetainedEarningsMember 2022-09-30 0001413119 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassAStockMember 2021-09-30 0001413119 us-gaap:CommonStockMember KBLB:CommonClassBStockMember 2021-09-30 0001413119 us-gaap:CommonStockMember KBLB:ClassASharesToBeIssuedMember 2021-09-30 0001413119 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001413119 us-gaap:RetainedEarningsMember 2021-09-30 0001413119 2021-09-30 0001413119 KBLB:StockWarrantsMember 2022-01-01 2022-09-30 0001413119 KBLB:StockWarrantsMember 2021-01-01 2021-12-31 0001413119 KBLB:StockOptionsMember 2022-01-01 2022-09-30 0001413119 KBLB:StockOptionsMember 2021-01-01 2021-12-31 0001413119 us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001413119 us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001413119 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-09-30 0001413119 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001413119 srt:MinimumMember 2022-09-30 0001413119 srt:MinimumMember 2021-12-31 0001413119 srt:MaximumMember 2022-09-30 0001413119 srt:MaximumMember 2021-12-31 0001413119 us-gaap:FairValueInputsLevel1Member 2022-09-30 0001413119 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001413119 us-gaap:FairValueInputsLevel2Member 2022-09-30 0001413119 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001413119 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001413119 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001413119 us-gaap:AutomobilesMember 2022-09-30 0001413119 us-gaap:AutomobilesMember 2021-12-31 0001413119 KBLB:LaboratoryEquipmentMember 2022-09-30 0001413119 KBLB:LaboratoryEquipmentMember 2021-12-31 0001413119 us-gaap:OfficeEquipmentMember 2022-09-30 0001413119 us-gaap:OfficeEquipmentMember 2021-12-31 0001413119 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001413119 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001413119 KBLB:OperatingLeaseAgreementsMember 2022-01-01 2022-09-30 0001413119 2017-01-22 2017-01-23 0001413119 KBLB:RemovalOfNewGuidanceMember 2021-04-05 0001413119 2019-09-05 0001413119 KBLB:OperatingLeaseAgreementsMember KBLB:OfficeAndManufacturingSpaceMember KBLB:JulyOneTwoThousandTwentyOneAndSeptemberThrityTwoThousandTwentyTwoMember 2022-01-01 2022-09-30 0001413119 KBLB:OperatingLeaseAgreementsMember KBLB:OctoberOneTwoThousandTwentyTwoThroughSeptemberThrityTwoThosuandTwentyThreeMember 2022-01-01 2022-09-30 0001413119 KBLB:AdoptionOfNewGuidanceMember 2022-09-30 0001413119 KBLB:SocialistRepublicOfVietnamMember 2019-05-09 0001413119 KBLB:SocialistRepublicOfVietnamMember 2019-05-09 2019-05-09 0001413119 2021-07-02 0001413119 KBLB:SocialistRepublicOfVietnamMember 2021-07-02 0001413119 KBLB:RightToUseAssetsNetMember 2022-09-30 0001413119 KBLB:RightToUseAssetsNetOneMember 2022-09-30 0001413119 KBLB:OperatingLeaseLiabilityNetMember 2022-09-30 0001413119 KBLB:OperatingLeaseLiabilityNetOneMember 2022-09-30 0001413119 KBLB:OperatingLeaseExpensesMember 2022-01-01 2022-09-30 0001413119 KBLB:OperatingLeaseExpensesOneMember 2022-01-01 2022-09-30 0001413119 2016-06-05 2016-06-06 0001413119 2017-11-30 2017-12-01 0001413119 2018-01-06 2018-01-08 0001413119 2018-03-29 2018-03-31 0001413119 2018-04-25 2018-04-26 0001413119 2018-06-20 2018-06-21 0001413119 2018-06-28 2018-06-29 0001413119 2018-07-04 2018-07-05 0001413119 2018-09-27 2018-10-01 0001413119 2018-10-11 2018-10-12 0001413119 2018-12-20 2018-12-21 0001413119 2019-01-03 2019-01-04 0001413119 2019-01-16 2019-01-17 0001413119 2019-01-29 2019-02-01 0001413119 2019-02-14 2019-02-15 0001413119 2019-03-01 2019-03-01 0001413119 KBLB:LoanOneMember 2019-01-03 2019-01-04 0001413119 2019-11-19 2019-11-20 0001413119 2019-12-17 2019-12-18 0001413119 2020-01-23 2020-01-24 0001413119 2020-02-18 2020-02-19 0001413119 2020-03-08 2020-03-09 0001413119 2020-04-07 2020-04-08 0001413119 2020-06-02 2020-06-03 0001413119 2020-07-15 2020-07-16 0001413119 2020-08-11 2020-08-12 0001413119 2020-09-09 2020-09-10 0001413119 2020-10-18 2020-10-19 0001413119 2020-11-03 2020-11-04 0001413119 2020-11-16 2020-11-17 0001413119 2020-11-30 2020-12-01 0001413119 2016-06-06 0001413119 2022-01-26 0001413119 KBLB:NotreDameMember KBLB:UnsecuredPromissoryNoteMember 2019-03-01 0001413119 KBLB:NotreDameMember KBLB:UnsecuredPromissoryNoteMember 2019-02-26 2019-03-01 0001413119 KBLB:UnsecuredPromissoryNoteMember 2022-01-01 2022-09-30 0001413119 KBLB:FirstNineMonthsMember 2022-01-01 2022-09-30 0001413119 KBLB:SevenAndEightMonthsMember 2022-01-01 2022-09-30 0001413119 KBLB:NineThroughTwentyThreeMonthsMember 2022-01-01 2022-09-30 0001413119 KBLB:TwentyFourthMonthsMember 2022-09-30 0001413119 2021-07-08 0001413119 KBLB:ThirteenMonthsMember 2022-01-01 2022-09-30 0001413119 KBLB:FourteenMonthsMember 2022-01-01 2022-09-30 0001413119 KBLB:TwentyMonthsMember 2022-01-01 2022-09-30 0001413119 KBLB:UnsecuredConvertibleNoteMember 2020-12-10 2020-12-11 0001413119 KBLB:UnsecuredConvertibleNoteMember 2020-12-11 0001413119 2020-12-10 2020-12-11 0001413119 2020-12-11 0001413119 KBLB:UnsecuredConvertibleNoteMember KBLB:FirstConvertibleDebentureMember 2020-12-11 0001413119 KBLB:UnsecuredConvertibleNoteMember KBLB:FirstConvertibleDebentureMember 2021-03-25 0001413119 KBLB:UnsecuredConvertibleNoteMember KBLB:FirstConvertibleDebentureMember 2021-03-24 2021-03-25 0001413119 KBLB:UnsecuredConvertibleNoteMember KBLB:SecoundConvertibleDebentureMember 2021-04-04 2021-04-06 0001413119 KBLB:UnsecuredConvertibleNoteMember KBLB:ThirdConvertibleDebentureMember 2021-04-21 2021-04-22 0001413119 2021-03-24 2021-03-25 0001413119 2021-03-25 0001413119 us-gaap:MeasurementInputSharePriceMember 2021-03-25 0001413119 us-gaap:MeasurementInputExercisePriceMember 2021-03-25 0001413119 us-gaap:MeasurementInputExpectedTermMember 2021-03-25 0001413119 us-gaap:MeasurementInputPriceVolatilityMember 2021-03-25 0001413119 us-gaap:MeasurementInputExpectedDividendRateMember 2021-03-25 0001413119 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-25 0001413119 KBLB:UnsecuredConvertibleNoteMember 2021-03-25 0001413119 us-gaap:CommonStockMember 2022-01-21 2022-01-21 0001413119 us-gaap:CommonStockMember 2022-01-30 2022-01-31 0001413119 us-gaap:CommonStockMember 2022-02-16 2022-02-16 0001413119 KBLB:UnsecuredConvertibleNoteMember 2022-01-17 2022-01-18 0001413119 KBLB:UnsecuredConvertibleNoteMember 2022-01-18 0001413119 KBLB:UnsecuredConvertibleNoteMember 2022-07-01 2022-09-30 0001413119 KBLB:UnsecuredConvertibleNoteMember 2022-09-30 0001413119 us-gaap:WarrantMember KBLB:UnsecuredConvertibleNoteMember 2022-07-01 2022-09-30 0001413119 us-gaap:WarrantMember KBLB:UnsecuredConvertibleNoteMember 2022-09-30 0001413119 2022-01-17 2022-01-18 0001413119 us-gaap:MeasurementInputSharePriceMember 2022-01-18 0001413119 us-gaap:MeasurementInputExpectedTermMember 2022-01-18 0001413119 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-18 0001413119 us-gaap:MeasurementInputExpectedDividendRateMember 2022-01-18 0001413119 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-18 0001413119 KBLB:UnsecuredConvertibleNoteMember 2022-01-01 2022-09-30 0001413119 us-gaap:CommonStockMember 2022-04-14 2022-04-14 0001413119 us-gaap:CommonStockMember 2022-04-14 0001413119 us-gaap:CommonStockMember 2022-04-29 2022-04-29 0001413119 us-gaap:CommonStockMember 2022-04-29 0001413119 us-gaap:CommonStockMember 2022-05-17 2022-05-17 0001413119 us-gaap:CommonStockMember 2022-05-17 0001413119 us-gaap:CommonStockMember 2022-06-06 2022-06-06 0001413119 us-gaap:CommonStockMember 2022-06-06 0001413119 us-gaap:CommonStockMember 2022-06-14 2022-06-14 0001413119 us-gaap:CommonStockMember 2022-06-14 0001413119 us-gaap:CommonStockMember 2022-06-21 2022-06-21 0001413119 us-gaap:CommonStockMember 2022-06-21 0001413119 us-gaap:CommonStockMember 2022-06-30 2022-06-30 0001413119 us-gaap:CommonStockMember 2022-06-30 0001413119 us-gaap:CommonStockMember 2022-07-19 2022-07-19 0001413119 us-gaap:CommonStockMember 2022-07-19 0001413119 us-gaap:CommonStockMember 2022-08-18 2022-08-18 0001413119 us-gaap:CommonStockMember 2022-08-18 0001413119 us-gaap:CommonStockMember 2022-09-08 2022-09-08 0001413119 us-gaap:CommonStockMember 2022-09-08 0001413119 us-gaap:CommonStockMember 2022-09-26 2022-09-26 0001413119 us-gaap:CommonStockMember 2022-09-26 0001413119 KBLB:UnsecuredConvertibleNoteMember 2022-04-07 2022-04-11 0001413119 KBLB:UnsecuredConvertibleNoteMember 2022-04-11 0001413119 us-gaap:MeasurementInputSharePriceMember 2020-12-11 0001413119 us-gaap:MeasurementInputExercisePriceMember 2020-12-11 0001413119 us-gaap:MeasurementInputExpectedTermMember 2020-12-11 0001413119 us-gaap:MeasurementInputPriceVolatilityMember 2020-12-11 0001413119 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-11 0001413119 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-11 0001413119 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2022-01-18 0001413119 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2022-01-18 0001413119 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001413119 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-09-30 0001413119 us-gaap:ConvertibleNotesPayableMember 2022-09-30 0001413119 KBLB:PurchaseAgreementMember us-gaap:InvestorMember 2019-03-07 2019-03-09 0001413119 KBLB:PurchaseAgreementMember us-gaap:InvestorMember 2019-03-09 0001413119 KBLB:PurchaseAgreementMember us-gaap:InvestorMember KBLB:ClassACommonStockAndTwoWarrantsMember 2019-03-07 2019-03-09 0001413119 KBLB:PurchaseAgreementMember us-gaap:InvestorMember KBLB:SixCentWarrantMember 2019-03-09 0001413119 KBLB:PurchaseAgreementMember us-gaap:InvestorMember KBLB:EightCentWarrantMember 2019-03-09 0001413119 KBLB:PurchaseAgreementMember us-gaap:WarrantMember 2019-03-09 0001413119 KBLB:PurchaseAgreementMember KBLB:WarrantOneMember 2019-03-09 0001413119 KBLB:PurchaseAgreementMember KBLB:WarrantTwoMember 2019-03-09 0001413119 KBLB:PurchaseAgreementMember KBLB:WarrantThreeMember 2019-03-09 0001413119 KBLB:PurchaseAgreementMember us-gaap:WarrantMember 2021-03-02 0001413119 KBLB:PurchaseAgreementMember KBLB:WarrantOneMember 2021-03-02 0001413119 KBLB:PurchaseAgreementMember KBLB:WarrantTwoMember 2021-03-02 0001413119 KBLB:PurchaseAgreementMember KBLB:WarrantTwoMember 2021-06-24 0001413119 KBLB:PurchaseAgreementMember KBLB:WarrantThreeMember 2021-03-02 0001413119 KBLB:PurchaseAgreementMember KBLB:WarrantFourMember 2021-03-02 0001413119 2022-02-13 2022-02-15 0001413119 us-gaap:CommonStockMember 2022-02-13 2022-02-15 0001413119 us-gaap:WarrantMember 2022-02-13 2022-02-15 0001413119 2021-01-24 2021-01-25 0001413119 KBLB:CommonStockWarrantsAndOptionsMember 2021-01-25 0001413119 KBLB:CommonStockWarrantsAndOptionsMember 2021-01-24 2021-01-25 0001413119 KBLB:CommonStockWarrantsAndOptionFMember 2021-01-24 2021-01-25 0001413119 KBLB:CommonStockWarrantsAndOptionMember 2022-01-01 2022-09-30 0001413119 KBLB:CommonStockWarrantsAndOptionMember 2020-02-18 2020-02-19 0001413119 KBLB:CommonStockWarrantsAndOptionsMember 2020-02-19 0001413119 KBLB:CommonStockWarrantsAndOptionsMember 2020-02-18 2020-02-19 0001413119 KBLB:CommonStockWarrantsAndOptionSevenMember 2022-01-01 2022-09-30 0001413119 KBLB:CommonStockWarrantsAndOptionOneMember 2020-02-18 2020-02-19 0001413119 KBLB:CommonStockWarrantsAndOptionOneMember 2020-02-19 0001413119 KBLB:CommonStockWarrantsAndOptionOneMember 2022-01-01 2022-09-30 0001413119 us-gaap:CommonClassAMember 2009-02-15 2009-02-16 0001413119 us-gaap:CommonClassBMember 2009-02-15 2009-02-16 0001413119 2009-02-15 2009-02-16 0001413119 us-gaap:CommonStockMember 2022-05-17 2022-06-17 0001413119 us-gaap:CommonStockMember 2022-02-16 0001413119 us-gaap:CommonStockMember 2022-01-21 0001413119 us-gaap:CommonStockMember 2022-01-31 0001413119 us-gaap:StockOptionMember 2020-02-18 2020-02-19 0001413119 us-gaap:WarrantMember 2022-09-30 0001413119 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001413119 KBLB:WarrantOneMember 2022-09-30 0001413119 KBLB:WarrantOneMember 2022-01-01 2022-09-30 0001413119 KBLB:WarrantTwoMember 2022-09-30 0001413119 KBLB:WarrantTwoMember 2022-01-01 2022-09-30 0001413119 KBLB:WarrantThreeMember 2022-09-30 0001413119 KBLB:WarrantThreeMember 2022-01-01 2022-09-30 0001413119 KBLB:WarrantFourMember 2022-09-30 0001413119 KBLB:WarrantFourMember 2022-01-01 2022-09-30 0001413119 KBLB:WarrantFiveMember 2022-09-30 0001413119 KBLB:WarrantFiveMember 2022-01-01 2022-09-30 0001413119 KBLB:WarrantSixMember 2022-09-30 0001413119 KBLB:WarrantSixMember 2022-01-01 2022-09-30 0001413119 KBLB:WarrantSevenMember 2022-09-30 0001413119 KBLB:WarrantSevenMember 2022-01-01 2022-09-30 0001413119 KBLB:WarrantEightMember 2022-09-30 0001413119 KBLB:WarrantEightMember 2022-01-01 2022-09-30 0001413119 KBLB:WarrantNineMember 2022-09-30 0001413119 KBLB:WarrantNineMember 2022-01-01 2022-09-30 0001413119 us-gaap:WarrantMember 2021-12-31 0001413119 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001413119 KBLB:WarrantOneMember 2021-12-31 0001413119 KBLB:WarrantOneMember 2021-01-01 2021-12-31 0001413119 KBLB:WarrantTwoMember 2021-12-31 0001413119 KBLB:WarrantTwoMember 2021-01-01 2021-12-31 0001413119 KBLB:WarrantThreeMember 2021-12-31 0001413119 KBLB:WarrantThreeMember 2021-01-01 2021-12-31 0001413119 KBLB:WarrantFourMember 2021-12-31 0001413119 KBLB:WarrantFourMember 2021-01-01 2021-12-31 0001413119 KBLB:WarrantFiveMember 2021-12-31 0001413119 KBLB:WarrantFiveMember 2021-01-01 2021-12-31 0001413119 KBLB:WarrantSixMember 2021-12-31 0001413119 KBLB:WarrantSixMember 2021-01-01 2021-12-31 0001413119 KBLB:WarrantSevenMember 2021-12-31 0001413119 KBLB:WarrantSevenMember 2021-01-01 2021-12-31 0001413119 KBLB:WarrantEightMember 2021-12-31 0001413119 KBLB:WarrantEightMember 2021-01-01 2021-12-31 0001413119 KBLB:WarrantNineMember 2021-12-31 0001413119 KBLB:WarrantNineMember 2021-01-01 2021-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2010-11-09 2010-11-10 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2015-01-01 2015-12-31 0001413119 KBLB:EmploymentAgreementMember KBLB:EmployeeMember 2015-01-01 2015-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2016-01-01 2016-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2017-01-01 2017-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2019-01-01 2019-12-31 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2022-01-01 2022-12-31 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2015-01-19 2015-01-20 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember KBLB:JanuaryTwoThousandAndFifteenWarrantMember 2015-01-20 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember KBLB:MayTwoThousandAndFifteenWarrantMember 2015-05-28 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2015-12-31 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2016-01-13 2016-01-14 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2016-01-14 0001413119 KBLB:EmploymentAgreementMember 2016-01-14 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2018-01-06 2018-01-09 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2019-08-08 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2019-04-25 2019-04-26 0001413119 KBLB:EmploymentAgreementMember KBLB:MrJonathanRRiceMember 2019-08-12 2019-08-15 0001413119 KBLB:MrRiceMember 2022-09-30 0001413119 KBLB:MrRiceMember 2021-12-31 0001413119 KBLB:EmploymentAgreementMember KBLB:MrKennethLeMember 2019-07-03 2019-07-03 0001413119 KBLB:EmploymentAgreementMember KBLB:MrKennethLeMember 2019-07-03 0001413119 srt:BoardOfDirectorsChairmanMember 2022-09-30 0001413119 srt:BoardOfDirectorsChairmanMember 2021-12-31 0001413119 KBLB:LicenseAgreementMember 2006-05-07 2006-05-08 0001413119 KBLB:LicenseAgreementMember 2007-01-01 2007-01-31 0001413119 KBLB:LicenseAgreementMember srt:MaximumMember 2007-01-01 2007-01-31 0001413119 KBLB:LicenseAgreementMember 2011-10-27 2011-10-28 0001413119 KBLB:LicenseAgreementMember 2011-10-28 0001413119 KBLB:ConsultingAgreementMember 2011-10-28 0001413119 KBLB:LicenseAgreementMember us-gaap:CommonClassAMember 2019-03-01 2019-03-01 0001413119 KBLB:LicenseAgreementMember 2022-01-01 2022-09-30 0001413119 KBLB:RoyaltyAndResearchAgreementsMember KBLB:MrThompsonMember 2006-12-25 2006-12-26 0001413119 KBLB:IntellectualPropertyTransferAgreementMember KBLB:MrThompsonMember 2022-09-30 0001413119 KBLB:IntellectualPropertyTransferAgreementMember KBLB:MrThompsonMember 2021-12-31 0001413119 KBLB:OperatingLeaseAgreementsMember KBLB:SocialistRepublicOfVietnamMember 2019-05-09 0001413119 KBLB:OperatingLeaseAgreementsMember KBLB:SocialistRepublicOfVietnamMember 2021-07-01 0001413119 KBLB:OperatingLeaseAgreementsMember KBLB:SocialistRepublicOfVietnamMember 2021-07-01 2021-07-01 0001413119 KBLB:OperatingLeaseAgreementsMember 2017-01-23 0001413119 KBLB:OperatingLeaseAgreementsMember KBLB:MonthlyRentMember 2017-01-22 2017-01-23 0001413119 KBLB:OperatingLeaseAgreementsMember KBLB:RelatedPartyMember 2021-01-01 2021-12-31 0001413119 KBLB:OperatingLeaseAgreementsMember KBLB:RelatedPartyMember 2020-01-01 2020-12-31 0001413119 2017-09-13 0001413119 KBLB:OperatingLeaseAgreementsMember 2019-09-04 2019-09-05 0001413119 KBLB:IntellectualPropertyTransferAgreementMember KBLB:MrThompsonMember 2006-12-25 2006-12-26 0001413119 KBLB:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember srt:ScenarioForecastMember 2022-01-01 2022-12-31 0001413119 KBLB:EmploymentAgreementMember 2018-01-06 2018-01-09 0001413119 KBLB:MrJonathanRRiceMember 2022-09-30 0001413119 KBLB:MrJonathanRRiceMember 2021-12-31 0001413119 KBLB:MrKennethLeMember 2022-09-30 0001413119 KBLB:MrKennethLeMember 2021-12-31 0001413119 KBLB:StockholderMember 2016-06-05 2016-06-06 0001413119 KBLB:StockholderMember 2017-11-30 2017-12-02 0001413119 KBLB:StockholderMember 2018-01-07 2018-01-08 0001413119 KBLB:StockholderMember 2018-03-30 2018-03-31 0001413119 KBLB:StockholderMember 2018-04-25 2018-04-26 0001413119 KBLB:StockholderMember 2018-06-20 2018-06-21 0001413119 KBLB:StockholderMember 2018-06-28 2018-06-29 0001413119 KBLB:StockholderMember 2018-07-04 2018-07-05 0001413119 KBLB:StockholderMember 2018-09-29 2018-10-01 0001413119 KBLB:StockholderMember 2018-10-11 2018-10-12 0001413119 KBLB:StockholderMember 2018-12-20 2018-12-21 0001413119 KBLB:StockholderMember 2019-01-03 2019-01-04 0001413119 KBLB:StockholderMember 2019-01-16 2019-01-17 0001413119 KBLB:StockholderMember 2019-01-29 2019-02-01 0001413119 KBLB:StockholderMember 2019-02-14 2019-02-15 0001413119 KBLB:StockholderMember 2019-03-01 2019-03-01 0001413119 KBLB:StockholderMember 2018-12-27 2019-01-04 0001413119 KBLB:StockholderMember 2019-11-19 2019-11-20 0001413119 KBLB:StockholderMember 2019-12-17 2019-12-18 0001413119 KBLB:StockholderMember 2020-01-23 2020-01-24 0001413119 KBLB:StockholderMember 2020-02-18 2020-02-19 0001413119 KBLB:StockholderMember 2020-03-08 2020-03-09 0001413119 KBLB:StockholderMember 2020-04-07 2020-04-08 0001413119 KBLB:StockholderMember 2020-06-02 2020-06-03 0001413119 KBLB:StockholderMember 2020-07-15 2020-07-16 0001413119 KBLB:StockholderMember 2020-08-11 2020-08-12 0001413119 KBLB:StockholderMember 2020-09-09 2020-09-10 0001413119 KBLB:StockholderMember 2020-10-18 2020-10-19 0001413119 KBLB:StockholderMember 2020-11-03 2020-11-04 0001413119 KBLB:StockholderMember 2020-11-16 2020-11-17 0001413119 KBLB:StockholderMember 2020-11-30 2020-12-01 0001413119 KBLB:StockholderMember 2016-06-06 0001413119 2022-01-25 2022-01-26 0001413119 KBLB:OperatingLeaseAgreementsMember srt:PresidentMember 2017-01-22 2017-01-23 0001413119 KBLB:RelatedPartyMember 2022-07-01 2022-09-30 0001413119 KBLB:RelatedPartyMember 2021-07-01 2021-09-30 0001413119 KBLB:ChiefExecutiveOfficerAndChiefOperationsOfficerMember 2022-09-30 0001413119 KBLB:ChiefExecutiveOfficerAndChiefOperationsOfficerMember 2021-12-31 0001413119 KBLB:RelatedPartyMember 2022-09-30 0001413119 KBLB:RelatedPartyMember 2021-12-31 0001413119 KBLB:PrincipalStockHoldersMember 2022-09-30 0001413119 KBLB:DirectorAndEmployeeMember 2022-09-30 0001413119 srt:ChiefOperatingOfficerMember 2022-09-30 0001413119 KBLB:OfficeEmployeesMember 2022-09-30 0001413119 KBLB:PrincipalStockHoldersMember 2021-12-31 0001413119 KBLB:DirectorAndEmployeeMember 2021-12-31 0001413119 srt:ChiefOperatingOfficerMember 2021-12-31 0001413119 KBLB:OfficeEmployeesMember 2021-12-31 0001413119 us-gaap:SubsequentEventMember 2022-10-11 2022-10-11 0001413119 us-gaap:SubsequentEventMember 2022-10-11 0001413119 us-gaap:SubsequentEventMember 2022-10-18 2022-10-18 0001413119 us-gaap:SubsequentEventMember 2022-10-18 0001413119 us-gaap:SubsequentEventMember 2022-10-26 2022-10-26 0001413119 us-gaap:SubsequentEventMember 2022-10-26 0001413119 us-gaap:SubsequentEventMember 2022-10-31 2022-10-31 0001413119 us-gaap:SubsequentEventMember 2022-10-31 0001413119 us-gaap:SubsequentEventMember 2022-11-01 2022-11-01 0001413119 us-gaap:SubsequentEventMember 2022-11-01 0001413119 us-gaap:SubsequentEventMember 2022-11-13 2022-11-14 0001413119 us-gaap:SubsequentEventMember 2022-11-14 0001413119 us-gaap:SubsequentEventMember KBLB:YorkvilleAdvisorsMember 2022-11-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft utr:sqm utr:oz

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

☐	TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from_____ to _____

Commission File Number: 000-56232

KRAIG BIOCRAFT LABORATORIES, INC.

(Exact Name of Registrant as Specified in Charter)

Wyoming

83-0459707

(State or Other Jurisdiction

of Incorporation)

(I.R.S. Employer

Identification No.)

2723 South State St. Suite 150

Ann Arbor, Michigan 48104

(Address of Principal Executive Offices)

(734) 619-8066

(Registrant’s telephone number, including area code)

(Former name and address, if changed since last report)

Copies to:

Hunter Taubman Fischer & Li LLC

48 Wall Street, Suite 1100

New York, NY 10005

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
None		-		-

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 14, 2022, there were 1,025,004,658 shares of the issuer’s Class A common stock, no par value per share, outstanding, 0 shares of the issuer’s Class B common stock, no par value per share, outstanding and 2 shares of preferred stock, no par value per share, outstanding.

TABLE OF CONTENTS

	Page

PART I FINANCIAL INFORMATION

Item 1. Unaudited Condensed Financial Statements:	3

Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and December 31, 2021 (Audited)	3

Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2022 and 2021	4

Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2022 (Unaudited)	5

Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2021 (Unaudited)	6

Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2022 and 2021	7

Notes to Condensed Consolidated Financial Statements (Unaudited)	8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	27

Item 3. Quantitative and Qualitative Disclosures about Market Risk	38

Item 4. Controls and Procedures	38

PART II OTHER INFORMATION

Item 1. Legal proceedings	39

Item 1A. Risk Factors	39

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	39

Item 3. Defaults upon Senior Securities	39

Item 4. Mine Safety Disclosures	39

Item 5. Other information	39

Item 6. Exhibits	39

Kraig Biocraft Laboratories, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

	September 30, 2022			December 31, 2021
		(Unaudited)
ASSETS
Current Assets
Cash	$	4,324,331		$	2,355,060
Prepaid expenses		162			11,055
Deposit		105,060			-
Total Current Assets		4,429,553			2,366,115

Property and Equipment, net		89,506			110,943
Investment in gold bullions (cost $450,216 and $450,216, respectively)		397,758			437,212
Operating lease right-of-use asset, net		70,501			104,124
Security deposit		3,518			3,518

Total Assets	$	4,990,836		$	3,021,912


LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities
Accounts payable and accrued expenses	$	683,800		$	587,794
Note payable - related party		1,617,000			1,657,000
Royalty agreement payable - related party		65,292			65,292
Accounts payable and accrued expenses - related party		5,527,299			5,244,560
Operating lease liability, current		49,479			44,577
Loan payable		65,292			60,000
Convertible note payable, net of debt discount of $398,600 and $246,577, respectively		701,400			503,423
Total Current Liabilities		8,709,562			8,162,646

Long Term Liabilities
Loan payable, net of current		44,952			95,244
Operating lease liability, net of current		22,421			59,897

Total Liabilities		8,776,935			8,317,787

Commitments and Contingencies (Note 9)		-			-

Stockholders’ Deficit
Preferred stock, no par value; unlimited shares authorized, none, issued and outstanding		-			-
Preferred stock Series A, no par value; 2 and 2 shares issued and outstanding, respectively		5,217,800			5,217,800
Preferred stock value		-			-
Common stock Class A, no par value; unlimited shares authorized, 990,105,794 and 927,378,166 shares issued and outstanding, respectively		25,927,831			22,385,132
Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding		-			-
Common stock value		-			-
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively		22,000			22,000
Additional paid-in capital		10,756,423			9,894,179
Accumulated Deficit		(45,710,153	)		(42,814,986	)

Total Stockholders’ Deficit		(3,786,099	)		(5,295,875	)

Total Liabilities and Stockholders’ Deficit	$	4,990,836		$	3,021,912

Kraig Biocraft Laboratories, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(Unaudited)

	September 30, 2022			September 30, 2021			September 30, 2022			September 30, 2021
	For the Three Months Ended						For the Nine Months Ended
	September 30, 2022			September 30, 2021			September 30, 2022			September 30, 2021

Revenue	$	-		$	-		$	-		$	-

Operating Expenses
General and Administrative		207,172			637,611			632,610			1,313,510
Professional Fees		87,220			33,179			317,134			259,702
Officer’s Salary		168,770			162,498			518,423			494,090
Rent - Related Party		-			-			-			3,683
Research and Development		62,118			39,254			139,491			171,748
Total Operating Expenses		525,280			872,542			1,607,658			2,242,733

Loss from Operations		(525,280	)		(872,542	)		(1,607,658	)		(2,242,733	)

Other Income/(Expenses)
Gain on debt extinguishment (PPP)		-			-			-			90,100
Net change in unrealized depreciation on investment in gold bullion		(34,053	)		(37,702	)		(39,454	)		(37,702	)
Interest expense		(74,747	)		(188,416	)		(535,078	)		(518,294	)
Amortization of debt issue costs		(176,276	)		(2,088,487	)		(712,977	)		(4,172,955	)
Total Other Income/(Expenses)		(285,076	)		(2,314,605	)		(1,287,509	)		(4,638,851	)

Net (Loss) before Provision for Income Taxes		(810,356	)		(3,187,147	)		(2,895,167	)		(6,881,584	)

Provision for Income Taxes		-			-			-			-

Net (Loss)	$	(810,356	)	$	(3,187,147	)	$	(2,895,167	)	$	(6,881,584	)

Net Income (Loss) Per Share - Basic and Diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)

Weighted average number of shares outstanding during the period - Basic and Diluted		976,587,869			879,561,355			960,027,786			865,640,011

Kraig Biocraft Laboratories, Inc. and Subsidiary

Condensed Consolidated Statement of Changes in Stockholders’ Deficit

For the three and nine months ended September 30, 2022

(Unaudited)

	Shares		Par		Shares		Par		Shares		Par		Shares		Par		APIC		Deficit			Total
	Preferred Stock -				Common Stock -				Common Stock -
	Series A				Class A				Class B				To be issued						Accumulated
	Shares		Par		Shares		Par		Shares		Par		Shares		Par		APIC		Deficit			Total
Balance, June 30, 2022 (Unaudited)		2	$	5,217,800		974,412,737	$	25,207,078		-	$	-		1,122,311	$	22,000	$	10,678,115	$	(44,899,797	)	$	(3,774,804	)

Warrants issued for services - related parties		-		-		-		-		-		-		-		-		49,913		-			49,913

Warrants issued for services		-		-		-		-		-		-		-		-		8,016		-			8,016

Convertible debt and accrued interest conversion into common stock ($0.042/Sh-$0.064/Sh)		-		-		15,693,057		720,753		-		-		-		-		-		-			720,753

Imputed interest - related party		-		-		-		-		-		-		-		-		20,379		-			20,379

Net loss for the three months ended September 30, 2022		-		-		-		-		-		-		-		-		-		(810,356	)		(810,356	)

Balance, September 30, 2022 (Unaudited)		2	$	5,217,800		990,105,794	$	25,927,831		-	$	-		1,122,311	$	22,000	$	10,756,423	$	(45,710,153	)	$	(3,786,099	)

	Preferred Stock -				Common Stock -				Common Stock -				Class A Shares
	Series A				Class A				Class B				To be issued						Accumulated
		Shares		Par		Shares		Par		Shares		Par		Shares		Par		APIC		Deficit			Total
Balance, December 31, 2021 (Audited)		2	$	5,217,800		927,378,166	$	22,385,132		-	$	-		1,122,311	$	22,000	$	9,894,179	$	(42,814,986	)	$	(5,295,875	)

Warrants issued for services - related parties		-		-		-		-		-		-		-		-		152,982		-			152,982

Warrants issued for services		-		-		-		-		-		-		-		-		23,787		-			23,787

Exercise of warrants in exchange for cash ($0.06/Sh and $0.08/Sh)		-		-		11,097,959		739,864		-		-		-		-		-		-			739,864

Convertible debt and accrued interest conversion into common stock ($0.042/Sh-$0.064/Sh))		-		-		51,629,669		2,802,835		-		-		-		-		-		-			2,802,835

Imputed interest - related party		-		-		-		-		-		-		-		-		60,472		-			60,472

Beneficial conversion feature		-		-		-		-		-		-		-		-		625,003		-			625,003

Net loss for the nine months ended September 30, 2022		-		-		-		-		-		-		-		-		-		(2,895,167	)		(2,895,167	)

Balance, September 30, 2022 (Unaudited)		2	$	5,217,800		990,105,794	$	25,927,831		-	$	-		1,122,311	$	22,000	$	10,756,423	$	(45,710,153	)	$	(3,786,099	)

Kraig Biocraft Laboratories, Inc. and Subsidiary

Condensed Consolidated Statement of Changes in Stockholders Deficit

For the nine and three months ended September 30, 2021

(Unaudited)

	Shares		Par		Shares		Par		Shares		Par		Shares		Par		APIC			Deficit			Total
													Common Stock -
	Preferred Stock -				Common Stock -				Common Stock -				Class A Shares
	Series A				Class A				Class B				To be issued							Accumulated
	Shares		Par		Shares		Par		Shares		Par		Shares		Par		APIC			Deficit			Total

Balance, December 31, 2020 (Audited)		2	$	5,217,800		854,410,001	$	17,122,236		-	$	-		1,122,311	$	22,000	$	5,833,583		$	(34,769,183	)	$	(6,573,564	)

Warrants issued for services - related parties		-	$	-		-	$	-	$	-	$	-	$	-	$	-	$	505,809		$	-		$	505,809

Warrants issued for services		-	$	-		-	$	-	$	-	$	-	$	-	$	-	$	78,693		$	-		$	78,693

Common stock issued for services		-	$	-		3,000,000	$	242,100	$	-	$	-	$	-	$	-	$	-		$	-		$	242,100

Cancellations of warrants		-	$	-		-	$	-	$	-	$	-	$	-	$	-	$	(42,707	)	$	-		$	(42,707	)

Exercise of 3,816,522 warrants in exchange for stock		-	$	-		3,816,522	$	470,091	$	-	$	-	$	-	$	-	$	(292,533	)	$	-		$	177,558

Convertible debt conversion into common stock ($0.0744 - $0.1540/Sh)		-	$	-		36,325,230	$	2,859,301	$	-	$	-	$	-	$	-	$	-		$	-		$	2,859,301

Imputed interest - related party		-	$	-		-	$	-	$	-	$	-	$	-	$	-	$	61,968		$	-		$	61,968

Beneficial conversion feature		-	$	-		-	$	-	$	-	$	-	$	-	$	-	$	3,670,000		$	-		$	3,670,000

Net loss for the nine months ended September 30, 2021		-	$	-		-	$	-	$	-	$	-	$	-	$	-	$	-		$	(6,881,584	)	$	(6,881,584	)

Balance, September 30, 2021 (Unaudited)		2	$	5,217,800		897,551,753	$	20,693,728		-	$	-		1,122,311	$	22,000	$	9,814,813		$	(41,650,767	)	$	(5,902,426	)

	Shares		Par		Shares		Par			Shares		Par		Shares		Par		APIC		Deficit			Total
														Common Stock -
	Preferred Stock -				Common Stock -					Common Stock -				Class A Shares
	Series A				Class A					Class B				To be issued						Accumulated
	Shares		Par		Shares		Par			Shares		Par		Shares		Par		APIC		Deficit			Total

Balance, June 30, 2021 (Unaudited)		2	$	5,217,800		868,038,875	$	18,636,669			-	$	-		1,122,311	$	22,000	$	9,572,046	$	(38,463,620	)	$	(5,015,105	)

Warrants issued for services - related parties		-	$	-		-	$	-		$	-	$	-	$	-	$	-	$	166,978	$	-		$	166,978

Warrants issued for services		-	$	-		-	$	-		$	-	$	-	$	-	$	-	$	54,906	$	-		$	54,906

Common stock issued for services		-	$	-		3,000,000	$	242,100		$	-	$	-	$	-	$	-	$	-	$	-		$	242,100

Convertible debt conversion into common stock ($0.0744 - $0.1108/Sh)		-	$	-		26,512,878	$	1,814,959		$	-	$	-	$	-	$	-	$	-	$	-		$	1,814,959
Convertible debt conversion into common stock		-	$	-		26,512,878	$	1,814,959		$	-	$	-	$	-	$	-	$	-	$	-		$	1,814,959

Imputed interest - related party		-	$	-		-	$	-		$	-	$	-	$	-	$	-	$	20,883	$	-		$	20,883

Net loss for the three months ended September 30, 2021		-	$	-		-	$	-		$	-	$	-	$	-	$	-	$	-	$	(3,187,147	)	$	(3,187,147	)

Balance, September 30, 2021 (Unaudited)		2	$	5,217,800		897,551,753	$	20,693,728	#		-	$	-		1,122,311	$	22,000	$	9,814,813	$	(41,650,767	)	$	(5,902,426	)

Kraig Biocraft Laboratories, Inc. and Subsidiary

Consolidated Statements of Cash Flows

	2022			2021
	For the nine months ended September 30,
	2022			2021
Cash Flows From Operating Activities:
Net Loss	$	(2,895,167	)	$	(6,881,584	)
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense		21,437			19,304
Gain on debt extinguishment (PPP)		-			(90,100	)
Net change in unrealized depreciation in gold bullions		39,454			37,702
Stock issued for services		-			242,100
Loss on disposal of fixed assets		-			49,321
Amortization of debt discount		712,977			4,172,955
Imputed interest - related party		60,472			61,968
Warrants issued/(cancelled) to consultants		176,769			541,795
Changes in operating assets and liabilities:
(Increase) Decrease in prepaid expenses		10,893			(6,581	)
(Increase) in deposits		(105,060	)		-
Operating lease right-of-use, net		33,623			79,290
Increase in accrued expenses and other payables - related party		282,739			283,273
Increase in accounts payable		248,844			178,883
Operating lease liabilities, current		(32,574	)		(93,985	)
Net Cash Used In Operating Activities		(1,445,593	)		(1,405,659	)

Cash Flows From Investing Activities:
Investment in gold bullions		-			(450,216	)
Purchase of Fixed Assets		-			(79,921	)
Net Cash Used In Investing Activities		-			(530,137	)

Cash Flows From Financing Activities:
Repayment of notes payable - related party		(40,000	)		-
Proceeds from convertible note payable, net of original issue discount		2,990,000			3,670,000
Payment of debt offering costs		(230,000	)		-
Principal payments on debt		(45,000	)		(35,000	)
Proceeds from warrant exercise		739,864			177,558
Net Cash Provided by Financing Activities		3,414,864			3,812,558

Net Increase in Cash		1,969,271			1,876,762

Cash at Beginning of Period		2,355,060			816,907

Cash at End of Period	$	4,324,331		$	2,693,669

Supplemental disclosure of cash flow information:

Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

Supplemental disclosure of non-cash investing and financing activities:
Shares issued in connection with cashless warrants exercise	$	-		$	292,533
Beneficial conversion feature in connection with convertible debt	$	-		$	3,670,000
Adoption of lease standard ASC 842	$	-		$	115,390
Cancellation and forgiveness of lease - related party	$	-		$	44,419
Cancellation and forgiveness of lease	$	-		$	241,800
Shares issued in connection with settlement of accounts payable	$	-		$	159,301
Shares issued in connection with convertible note payable	$	2,802,835		$	2,859,301

Kraig Biocraft Laboratories, Inc.

Notes to Condensed Consolidated Financial Statements as of September 30, 2022

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

(A) Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations.

It is management’s opinion, however that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statements presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year.

On July 15, 2022, the Company signed an agreement with Global Silk Solutions Joint Stock Company (GSS). Under this agreement, GSS will serve as a contract manufacturer for the Company’s recombinant spider silk.

Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries.

On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary.

On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.

On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd

Foreign Currency

The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date.

Use of Estimates

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

Cash

For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents as of September 30, 2022 or December 31, 2021.

Loss Per Share

Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For September 30, 2022 and December 31, 2021, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive.

The computation of basic and diluted loss per share for September 30, 2022 and 2021 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive:

	September 30, 2022		December 31, 2021

Stock Warrants (Exercise price - $0.001- $0.25/share)		54,660,032		48,972,277
Stock Options (Exercise price - $0.1150/Share)		26,802,500		26,802,500
Convertible Debt		17,412,783		6,470,674
Convertible Preferred Stock		2		2
Total		98,875,319		82,245,453

Research and Development Costs

The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.

Income Taxes

The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-Based Compensation

The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations.

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07.

Recent Accounting Pronouncements

Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company.

In September 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842), which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for the Company in the first quarter of fiscal year beginning January 1, 2023, and early adoption is permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard did not have a material effect on the Company’s financial statements.

In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard did not have a material effect on the Company’s financial statements. However, based on the Company’s history of immaterial credit losses from trade receivables, management does not expect that the adoption of this standard will have a material effect on the Company’s financial statements.

In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company adopted the guidance under ASU 2020-06 on January 1, 2022. The adoption of this guidance and had no material impact on the Company’s financial statements.

Equipment

The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life.

In accordance with FASB ASC No. 360, Property, Plant and Equipment, the Company carries long-lived assets at the lower of the carrying amount or fair value. Impairment is evaluated by estimating future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected undiscounted future cash flow is less than the carrying amount of the assets, an impairment loss is recognized. Fair value, for purposes of calculating impairment, is measured based on estimated future cash flows, discounted at a market rate of interest.

There were no impairment losses recorded for the three and nine months ended September 30, 2022 and 2021.

Fair Value of Financial Instruments

We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” (“ASC Topic 820-10”). ASC Topic 820-10 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). ASC Topic 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Level 1 instruments include cash, account receivable, prepaid expenses, inventory and account payable and accrued liabilities. The carrying values are assumed to approximate the fair value due to the short term nature of the instrument.

The three levels of the fair value hierarchy under ASC Topic 820-10 are described below:

	●	Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at September 30, 2022 and 2021.

	●	Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

	●	Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms.

	September 30, 2022		December 31, 2021
Level 1 – Investment in Gold	$	397,758	$	437,212
Level 2	$	-	$	-
Level 3	$	-	$	-
Total	$	397,758	$	437,212

The Board of Directors, who serves as the Custodian, is responsible for the safekeeping of gold bullion owned by the Company.

Fair value of the gold bullion held by the Company is based on that day’s London Bullion Market Association (“LBMA”) Gold Price PM. “LBMA Gold Price PM” is the price per fine troy ounce of gold, stated in U.S. dollars, determined by ICE Benchmark Administration (“IBA”) following an electronic auction consisting of one or more 30-second rounds starting at 3:00 p.m. (London time), on each day that the London gold market is open for business and published shortly thereafter.

The following tables summarize activity in gold bullion for the quarter ended September 30, 2022:

SCHEDULE OF GOLD IN BULLION

Quarter Ended September 30, 2022	Ounces		Cost		Fair Value

Balance December 31, 2021		239	$	1,884	$	437,212
Net change in unrealized loss		-		-		(39,454	)
Ending balance		239	$	1,884	$	397,758

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

For the three and nine months ended September 30, 2022 and 2021, the Company recognized $0 and $0 respectively in revenue.

Concentration of Credit Risk

The Company at times has cash in banks in excess of FDIC insurance limits. At September 30, 2022 and December 31, 2021, the Company had approximately $3,750,272 and $2,092,420, respectively in excess of FDIC insurance limits.

Original Issue Discount

For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to amortization of original issue discount in the consolidated statements of operations over the life of the debt.

Debt Issue Cost

Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument.

NOTE 2 GOING CONCERN

As reflected in the accompanying condensed unaudited financial statements, the Company has a working capital deficiency of $4,280,009 and stockholders’ deficiency of $3,786,099 and used $1,445,593 of cash in operations for the nine months ended September 30, 2022. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

NOTE 3 EQUIPMENT

At September 30, 2022 and December 31, 2021, property and equipment, net, is as follows:

SCHEDULE OF PROPERTY AND EQUIPMENT

	September 30, 2022			December 31, 2021
Automobile	$	41,805		$	41,805
Laboratory Equipment		118,890			118,890
Office Equipment		7,260			7,260
Leasehold Improvements		82,739			82,739
Total Property and Equipment, gross		82,739			82,739
Less: Accumulated Depreciation		(161,188	)		(139,751	)
Total Property and Equipment, net	$	89,506		$	110,943

Depreciation expense for the three months ended September 30, 2022 and 2021, was $6,716 and $5,858, respectively.

Depreciation expense for the nine months ended September 30, 2022 and 2021, was $21,437 and $19,304, respectively.

NOTE 4 - RIGHT TO USE ASSETS AND LEASE LIABILITITY

Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $2,508 for conference facilities, mail, fax, and reception services located at our principal place of business.

On January 23, 2017 the Company signed an 8 year property lease with the Company’s President for land in Texas where the Company grows its mulberry. The Company pays a monthly rent of $960. Rent expense – related party for the three months ended September 30, 2022 and 2021, was $0 and $3,683, respectively (See Note 9). On April 5, 2021, the Company ended this lease agreement with its President and removed the associated ROU asset and lease liability of $44,419.

On September 5, 2019, we signed a two-year lease for a 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters. We pay an annual rent of $42,000 for year one of the lease and will pay $44,800 for year two of the lease. On April 16, 2021, the Company signed a two year amendment to this lease. Commencing on July 1, 2021 and ending on September 30, 2022, the Company will pay an annualized rent of $42,000. From October 1, 2022 through September 30, 2023, the Company will pay an annual rent of $44,800. The Company recorded ROU asset of $79,862 and lease liability of $79,862 in accordance with the adoption of the new guidance.

On May 9, 2019 the Company signed a 5 year property lease with the Socialist Republic of Vietnam which consists of 4,560.57 square meters of space, which it leases at a current rent of approximately $45,150 per year one and two and with the 5% increase per year for years three through five. On July 1, 2021, the Company ended this lease agreement, and the company recovered the associated ROU asset and lease liability of $241,800.

On July 1, 2021, the Company signed a 5-year property lease with the Socialist Republic of Vietnam which consists of 6,000 square meters of space, which it leases at a current rent of approximately $8,645 per year.

Right to use assets is summarized below:

SCHEDULE OF RIGHT USE OF ASSETS

	September 30, 2022
Right to use assets, net		41,517
Right to use assets, net		28,984
Total	$	70,501

During the nine months ended September 30, 2022, the Company recorded $27,275 as lease expense to current period operations.

Lease liability is summarized below:

SCHEDULE OF LEASE LIABILITY

	September 30, 2022
Operating lease liability, net		42,916
Operating lease liability, net		28,984
Total		71,900
Less: short term portion		(49,479	)
Long term position	$	22,421

Lease expense for the nine months ended September 30, 2022 was comprised of the following:

SCHEDULE OF LEASE EXPENSES


Operating lease expense	$	32,549
Operating lease expense	$	5,763

NOTE 5 ACCRUED INTEREST – RELATED PARTY

On June 6, 2016, the Company received a $50,000 loan from our principal stockholder. Subsequently on December 1, 2017, the Company received an additional $30,000 loan from the same stockholder. On January 8, 2018 and March 31, 2018, the Company received an additional loan of $100,000 and $15,000, respectively. The Company received additional loan funds from the same stockholder as follows: $20,000 on April 26, 2018; $15,000 on June 21, 2018; $15,000 on June 29, 2018; $20,000 on July 5, 2018; $26,000 on October 1, 2018; $11,000 on October 12, 2018; $20,000 on December 21, 2018; $3,000 on January 4, 2019; $30,000 on January 17, 2019; $30,000 on February 1, 2019; $20,000 on February 15, 2019; $20,000 on March 1, 2019; $17,000 on January 4, 2019, $100,000 on November 20, 2019, $100,000 on December 18, 2019, $100,000 on January 24, 2020, $100,000 on February 19, 2020 $100,000 on March 9, 2020, $100,000 on April 8, 2020, $150,000 on June 3, 2020, $100,000 on July 16, 2020, $100,000 on August 12, 2020,$100,000 on September 10, 2020, $30,000 on October 19, 2020, $30,000 on November 4, 2020, $35,000 on November 17, 2020 and $70,000 on December 1, 2020. Pursuant to the terms of the loan, the advances bear an interest at 3%, is unsecured, and due on demand.

On January 26, 2022, the Company repaid $40,000 of the outstanding loan to its principal stockholder.

Total loan payable to principal stockholder for as of September 30, 2022 is $1,617,000.

Total loan payable to this principal stockholder as of December 31, 2021 is $1,657,000.

During the nine months ended September 30, 2022, the Company recorded $60,472 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $40,962.

During the nine months ended September 30, 2021, the Company recorded $61,968 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $40,138.

NOTE 6 NOTE PAYABLE

On March 1, 2019, the Company entered into an unsecured promissory note with Notre Dame - an unrelated party in the amount of $265,244 in exchange for outstanding account payable due to the debtor. Pursuant to the terms of the note, the note bears 10% interest per year from the date of default until the date the loan is paid in full. The term of the loan is twenty-four months. The loan repayment commenced immediately over a twenty-four month period according to the following table. During the nine months ended September 30, 2022, the Company paid $45,000 of the loan balance (See Note 8 (A)):

1. $1,000 per month for the first nine months;

2. $2,000 per month for the months seven and eight;

3. $5,000 per month for months nine through twenty-three; and,

4. Final payment of all remaining balance, in the amount of $180,224 in month 24.

On July 8, 2021, the Company entered into an amendment to the March 1, 2019 agreement. As of the date of the amendment, the remaining outstanding balance is $180,244. The loan repayment commenced immediately following the amendment and will extend over a fourteen-month period with the following terms:

1.	$5,000 per month for months one through thirteen.
2.	Final payment of the remaining balance in the amount of $115,244 split into two equal payments, of which $57,622 to be paid in month fourteen and $57,622 paid in month twenty.

NOTE 7 CONVERTIBLE NOTES

The Company issued a $1,000,000, thirteen-month (13), unsecured, convertible note on December 11, 2020, which is due January 11, 2022. The convertible note bears interest at 10%, with a 5% original issue discount ($50,000), resulting in net proceeds of $950,000. The note contains a discount to market feature, whereby, the lender can purchase stock at 90% of the lowest trading price for a period of ten (10) days preceding the conversion date.

Additionally, the Company issued 3,125,000 five-year (5) warrants. The warrants had a fair value of $2,599,066, based upon using a black-scholes option pricing model with the following inputs:

SCHEDULE OF FAIR VALUE WARRANTS

Stock Price	$	0.14
Exercise price	$	0.16
Expected term (in years)		5
Expected volatility		60.64	%
Annual rate of quarterly dividends		0	%
Risk free interest rate		0.10	%

The Company has determined that ASC 815 does not apply since the Company has unlimited authorized shares, which in turn satisfies the requirement of having sufficient authorized shares available to settle any potential instruments that may require physical net-share settlement.

Pursuant to ASC 470, the Company will record a beneficial conversion feature (“BCF”) based upon the relative fair value of the conversion feature within the convertible note and the related warrants. The BCF cannot exceed the face amount of the note, therefore, the discount for this note is $1,000,000, and was recorded on the commitment date. The discount is amortized to amortization of debt discount over the life of the underlying convertible note.

The Company also paid $86,000 as a debt issuance cost to a placement agent for services rendered. These costs are considered to be a component of the total debt discount.

On March 25, 2021, the Company entered into one year, unsecured, convertible note in the aggregate principal amount of $4,000,000 for which the first convertible debenture for $500,000, a one year, unsecured, convertible note on March 25, 2021, which is due March 25, 2022. The convertible note bears interest at 10%. The note contains a discount to market feature, whereby, the lender can purchase stock at 80% of the lowest trading price for a period of ten (10) days preceding the conversion date. The second convertible debenture of $500,000 was issued on April 6, 2021 and the third convertible debenture of $3,000,000 was issued on April 22, 2021.

Additionally, the Company issued 8,000,000 five-year (5) warrants. The warrants had a fair value of $3,359,716, based upon using a black-scholes option pricing model with the following inputs:

Stock Price	$	0.15
Exercise price	$	0.25
Expected term (in years)		5
Expected volatility		100.76	%
Annual rate of quarterly dividends		0	%
Risk free interest rate		0.07	%

Pursuant to ASC 470, the Company will record a beneficial conversion feature (“BCF”) based upon the relative fair value of the conversion feature within the convertible note and the related warrants. The BCF cannot exceed the face amount of the note, therefore, the discount for this note is $3,670,000, and was recorded on the commitment date. The discount is amortized to amortization of debt discount over the life of the underlying convertible note.

The Company also paid $330,000 as a debt issuance cost to a placement agent for services rendered. These costs are a component of the total debt discount.

On January 21, 2022, the Company issued 3,935,417 shares of Common Stock in exchange for conversion of $250,000 of principle balance on a convertible debenture and $2,260 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On January 31, 2022, the Company issued 4,569,059 shares of Common Stock in exchange for conversion of $250,000 of principle balance on a convertible debenture and $42,877 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On February 16, 2022, the Company issued 3,924,443 shares of Common Stock in exchange for conversion of $250,000 of principle balance on a convertible debenture and $1,164 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

As of September 30, 2022, the above two notes were fully converted, with the no remaining balance due.

The Company issued a $1,500,000, thirteen-month (13), unsecured, convertible note on January 18, 2022, which is due February 18, 2023. The convertible note bears interest at 10%, with a original issue discount ($10,000), resulting in net proceeds of $1,490,000. The note contains a discount to market feature, whereby, the lender can purchase stock at 85% of the lowest trading price for a period of ten (10) days preceding the conversion date.

Additionally, the Company issued 12,000,000 five-year (5) warrants with an exercise price of $0.12 per share, and 4,285,714 warrants with an exercise price of $0.14 per share during the three months ended September 30, 2022. The warrants had a fair value of $1,071,437, based upon using a black-scholes option pricing model with the following inputs:

Stock Price	$	0.08
Exercise price	$	0.12
Exercise price	$	0.14
Expected term (in years)		5
Expected volatility		124.10	%
Annual rate of quarterly dividends		0	%
Risk free interest rate		0.58	%

In connection with $1,500,000 in note issued, the Company issued 16,785,714 warrants, which are accounted for as debt issue costs, having a fair value of $625,003. The debt issue costs is amortized over the life of the underlying convertible note.

The Company also paid $115,000 as a debt issuance cost to a placement agent for services rendered. These costs are considered to be a component of the total debt discount.

On April 14, 2022, the Company issued 2,358,380 shares of Common Stock in exchange for conversion of $150,000 of principle balance on a convertible debenture and $1,644 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On April 29, 2022, the Company issued 4,272,417 shares of Common Stock in exchange for conversion of $250,000 of principle balance on a convertible debenture and $5,918 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On May 17, 2022, the Company issued 3,628,325 shares of Common Stock in exchange for conversion of $200,000 of principle balance on a convertible debenture and $5,726 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On June 6, 2022, the Company issued 3,549,793 shares of Common Stock in exchange for conversion of $200,000 of principle balance on a convertible debenture and $5,178 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On June 14, 2022, the Company issued 2,902,922 shares of Common Stock in exchange for conversion of $100,000 of principle balance on a convertible debenture and $60,822 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On June 21, 2022, the Company issued 3,393,979 shares of Common Stock in exchange for conversion of $150,000 of principle balance on a convertible debenture and $3,068 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On June 30, 2022, the Company issued 3,401,877 shares of Common Stock in exchange for conversion of $150,000 of principle balance on a convertible debenture and $3,425 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On July 19, 2022, the Company issued 4,364,987 shares of Common Stock in exchange for conversion of $200,000 of principle balance on a convertible debenture and $6,027 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On August 18, 2022, the Company issued 4,325,913 shares of Common Stock in exchange for conversion of $200,000 of principle balance on a convertible debenture and $7,644 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On September 8, 2022, the Company issued 3,396,898 shares of Common Stock in exchange for conversion of $150,000 of principle balance on a convertible debenture and $4,219 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

On September 26, 2022, the Company issued 3,605,259 shares of Common Stock in exchange for conversion of $150,000 of principle balance on a convertible debenture and $2,863 of accrued interest. Accordingly, no gain or loss was recognized upon debt conversion.

The Company issued a $1,500,000, thirteen-month (13), unsecured, convertible note on April 11, 2022, which is due May 11, 2023. The convertible note bears interest at 10%. The note contains a discount to market feature, whereby, the lender can purchase stock at 85% of the lowest trading price for a period of ten (10) days preceding the conversion date.

The Company also paid $115,000 as a debt issuance cost to a placement agent for services rendered. These costs are considered to be a component of the total debt discount.

The following represents a summary of the Company’s convertible debt at September 30, 2022:

SUMMARY OF CONVERTIBLE DEBT

Convertible Note Payable

	Amounts			In-Default
Balance – December 31, 2021	$	503,423		$	-
Proceeds – net		3,000,000			-
Debt discount and issue costs recorded		(865,000	)		-
Conversion of debt into common shares		(2,650,000	)
Amortization of debt discount		712,977			-
Balance – September 30, 2022	$	701,400		$	-

Accrued Interest Payable

	Amounts			In-Default
Balance – December 31, 2021	$	31,657		$	-
Interest Expense September 30, 2022		236,151			-
Interest conversion into common shares		(183,740	)
Balance – September 30, 2022	$	84,068		$	-

NOTE 8 STOCKHOLDERS’ DEFICIT

(A) Common Stock Issued for Cash

On March 9, 2019, the Company entered into a purchase agreement with one investor (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company issued the investor 14,797,278 Units at a purchase price of $0.06758 per Unit, for total gross proceeds to the Company of $1,000,000. The Units consist of 14,797,278 shares of the Company’s Class A Common Stock (the “Common Stock”) and two warrants (the “Warrants”): (i) one warrant entitles the investor to purchase up to 14,797,278 shares of Common Stock at an exercise price of $0.06 per share (the “6 Cent Warrants”) and (ii) one warrant entitles the investor to purchase up to 7,398,639 shares of Common Stock at an exercise price of $0.08 per share (the “8 Cent Warrant”). The Warrants shall be exercisable at any time from the issuance date until the following expiration dates:

●	½ of all $0.06 Warrants shall expire on March 8, 2021;
●	½ of all $0.06 Warrants shall expire on March 8, 2022;
●	½ of all $0.08 Warrants shall expire on March 8, 2022; and,
●	½ of all $0.08 Warrants shall expire on March 8, 2023.

On March 2, 2021, the Company determined to amend and extend the expiration of the warrants expiring on March 8, 2021 as follows:

	●	1,479,728 shares of all $0.06 Warrants shall expire on March 8, 2021.
	●	1,479,728 shares of all $0.06 Warrants shall expire on May 8, 2021
	●	1,479,728 shares of all $0.06 Warrants shall expire on July 8, 2021. On June 24, 2021, the Company determined to amend and extend the expiration of warrants expiring on July 8, 2021, to December 8, 2021.

Boards:

Quotes:

KBLB